Simparica Trio (sarolaner, moxidectin, and pyrantel) has become one of the most-prescribed monthly parasite preventives for dogs since its 2020 FDA approval, covering fleas, ticks, heartworm, roundworms, and hookworms in a single chew. Because it contains sarolaner — a member of the isoxazoline class the FDA has flagged for neurologic adverse reactions — the question owners ask most is some version of "is this the one that causes seizures?" The honest answer is that seizures are the single most-reported reaction in the public FDA data, and that the same data also shows the overwhelming majority of dogs do fine.

To put real numbers on what gets reported, VetMedGuide analyzed the FDA Center for Veterinary Medicine (CVM) public adverse-event database, a June 2026 extract of 1.34 million reports. We identified reports for Simparica Trio and tabulated their reactions, outcomes, and history. Two things shape the analysis and should be stated up front: seizure is the leading reported reaction, consistent with the isoxazoline-class warning; and the total number of identifiable reports is modest because of how the FDA structures this particular public dataset (explained below).

How we identified reports (and why the count is conservative)

FDA's public adverse-event database masks brand names — every product is recorded as "MSK." That means a product has to be identified by its active ingredients. Simparica Trio's three-ingredient signature (sarolaner + moxidectin + pyrantel) is unique to this product; no other approved canine parasiticide combines all three. We therefore matched reports in which all three actives were explicitly recorded together.

This captured 131 reports, of which 103 named the species as dog (the rest were unspecified or, in one case, a human — likely accidental exposure). Sixty-eight were single-product reports (only Simparica Trio listed), the cleanest possible match.

This is a conservative lower bound, not the true total. The database does not consistently list every active ingredient for a combination product, so many genuine Simparica Trio reports are not captured by a strict three-ingredient match. The figures below describe this identifiable cohort and should be read as directional, not exhaustive. The FDA cautions, as it does for all spontaneous-report data, that these reports cannot establish causation or true event rates.

Seizure leads the reported reactions

Two clusters stand out. The first is neurologic: seizure (26), ataxia (7), and shaking/tremor (6) together account for the most distinctive signal. This is precisely the reaction pattern the FDA's isoxazoline-class alert describes — tremors, ataxia, and seizures — and it is why the Simparica Trio label carries a "use with caution in dogs with a history of seizures" precaution. The second is gastrointestinal: vomiting and diarrhea, which the label lists as the most common side effects seen in clinical trials.

Notably, in this spontaneous-report cohort seizure sits at the top, ahead of vomiting and diarrhea — the reverse of the label's pre-approval clinical-trial ranking (where vomiting and diarrhea were most common and neurologic events were not observed). That is the expected difference between a controlled trial of healthy dogs and a real-world reporting system that disproportionately captures the serious, alarming events owners and veterinarians are moved to report.

How to read the "X percent of dogs had seizures" claims online

Owners searching this topic quickly encounter alarming figures — "20% of dogs on Simparica had seizures," or an EMA-derived number in a similar range. Those percentages come from counting seizure reports against the number of reports filed, not against the number of doses given. That is a crucial difference. A population that generates 1,000 reports out of 10 million doses can have seizure appear in 20% of those 1,000 reports while the true per-dose seizure rate remains far below 1% — and many of those seizure reports involve dogs that already had epilepsy, since an isoxazoline is exactly the product an owner of a seizuring dog will suspect and report. Any analysis that does not separate dogs with prior seizure history from those with a first-ever event, and that has no denominator of doses exposed, overstates risk. The defensible reading is the one the FDA and the label support: seizure is a real, documented, class-level adverse reaction worth taking seriously, and the absolute risk to a neurologically normal dog on label-directed dosing is low.

Outcomes: serious but rarely fatal in this cohort

About a quarter of these reports (26.7%) carried a "serious" adverse-event flag. Death or euthanasia appeared in 15 of 131 reports (11.5%). As with every spontaneous-reporting analysis, that figure is not a mortality rate: serious events are over-reported and mild events are under-reported, the population includes dogs with pre-existing disease, and a report naming a drug does not establish the drug caused the outcome. What the death-outcome count does confirm is that severe, sometimes fatal neurologic events in dogs receiving Simparica Trio reach the level of an FDA report — which is itself the reason the isoxazoline class warning exists.

A reporting history that tracks the product's rollout

Reports climb after the 2020 launch and remain steady through 2025. This tracks a product moving from newly approved to widely used — more doses in the field mean more reports in absolute terms, even at a low per-dose rate. In 2022 Zoetis publicly noted that the global reporting rate for any clinical sign with Simparica Trio was classified "very rare" (fewer than 1 report per 10,000 doses administered), and that the product had been used in over 10 million dogs; the FDA approved an additional flea-tapeworm prevention indication in April 2025.

A manufacturing and counterfeit signal worth knowing

Seven reports named "suspect counterfeit product" and six named "lot number and/or expiration date incorrect," with a broader manufacturing/product-defect category appearing across the cohort. This is not unique to Simparica Trio — high-demand, premium-priced parasiticides are a known target for counterfeiting and gray-market diversion — but it is a reason to obtain the product through a veterinarian or a verified pharmacy rather than from unverified online sellers, and to check that the lot number and expiration date on the packaging are legible and consistent. A product that arrives with damaged packaging, a smudged lot number, or an unusually low price warrants a call to the prescribing clinic before it is given.

Who is reporting

Owners are the largest single reporter group — a pattern that reflects how visible and distressing a seizure is to an owner, and how social-media discussion has raised awareness of the isoxazoline-class signal. Veterinarian and technician reports make up most of the rest.

How to read the isoxazoline warning in practice

The FDA considers isoxazoline products safe and effective for the majority of dogs, and Simparica Trio remains FDA-approved with its neurologic warning stated plainly on the label. The decision points that matter:

• Dogs with a seizure history. The label says use with caution. For a dog with active epilepsy or recent seizures, a non-isoxazoline preventive (for example, a moxidectin or milbemycin-based heartworm product paired with a non-isoxazoline flea approach) is worth discussing with the veterinarian.
• Timing of signs. Neurologic signs from isoxazolines, when they occur, typically appear within hours to a few days of dosing. A seizure in that window is the pattern to report and to flag to the clinic before the next dose.
• Do not double-dose. If a dose is vomited or spit out, do not re-dose without checking with the veterinarian — overlap increases exposure.
• Emergency signs. Prolonged seizure activity (status epilepticus), repeated seizures, or profound unresponsiveness are emergencies.

If you suspect a reaction to Simparica Trio, report it — ask your veterinarian to file an adverse drug event report with Zoetis and the FDA, or submit one directly through the FDA's animal adverse-event reporting system. These reports are the raw material the agency uses to monitor class-wide safety signals, and analyses like this one depend on them.

Sources

• FDA CVM, animal adverse-event database (public extract, June 2026); analysis by VetMedGuide. The FDA cautions that spontaneous reports do not establish causation or true event rates. https://www.fda.gov/animal-veterinary/safety-health/reporting-animal-drug-and-device-side-effects-and-product-problems
• Simparica Trio (sarolaner, moxidectin, pyrantel) prescribing information, DailyMed (post-approval adverse events in decreasing order; isoxazoline neurologic warning). https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0f83bcf4-7e89-479f-a980-4cb40456ee78
• FDA, "FDA Approves Simparica Trio, a Combination Drug for Heartworm and Other Parasites" (March 2, 2020; NADA 141-521). https://www.fda.gov/animal-veterinary/cvm-updates/fda-approves-simparica-trio-combination-drug-heartworm-and-other-parasites
• FDA, isoxazoline flea-and-tick product fact sheet for pet owners and veterinarians (neurologic adverse reactions, including tremors, ataxia, and seizures). https://www.fda.gov/animal-veterinary/animal-health-literacy/fact-sheet-pet-owners-and-veterinarians-about-potential-adverse-events-associated-isoxazoline-flea
• FOI Summary, NADA 141-521, Simparica Trio original approval (February 27, 2020) and supplemental approval (April 8, 2025, flea-tapeworm prevention indication). https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/16785